OB/GYN Clinical Alert – July 1, 2024

Safety of Non-Insulin Antidiabetic Medications in Early Pregnancy

A multinational cohort study of more than 50,000 pregnant people found that those with periconceptual use of non-insulin antidiabetic medications, such as sulfonylureas, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 agonists, or sodium-glucose cotransporter 2 inhibitors, did not have increased risk of congenital malformations compared to those who used insulin periconceptually.

Targeting Vasomotor Symptoms with a Neurokinin-3 Receptor Antagonist

A meta-analysis of five randomized controlled studies showed that fezolinetant improved moderate-to-severe vasomotor symptoms with a pooled mean difference of 2.62 episodes per day (95% confidence interval [CI], 1.85-3.41) and had no significant adverse effects compared to placebo (odds ratio, 1.01; 95% CI, 0.84-1.22).

What Do Clinicians Think About the American Cancer Society Cervical Cancer Screening Guidelines?

In this study of provider attitudes toward the American Cancer Society 2020 cervical cancer screening guidelines that recommend deferring screening until age 25 years and using human papilloma virus alone as the primary screening, most providers had not adopted the guidelines and were waiting for endorsement by other professional societies, such as the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology.

Furosemide for the Management of Postpartum Hypertension

Current evidence does not support the effectiveness of furosemide in reducing the mean arterial pressure within 24 hours before discharge from delivery hospitalization or before starting antihypertensive medications, compared to a placebo.